Clinical trial oversight is reactive by design. Operations depends on periodic, often manual review, resulting in delayed signal detection. This model is breaking under modern trial complexity.
That model is breaking under modern trial complexity.
At the same time, the industry is moving toward something fundamentally different: continuous, event-based oversight, where emerging risks and execution drift are detected and acted on in real time rather than weeks later via traditional reporting cycles.
OmniScience is building for that shift.
With Vivo, our agentic AI platform for clinical trial oversight, sponsors can continuously monitor trial execution, interpret what’s changing, and take confident action while meaningful options still exist.
In most trials, early warning signs show up in the data long before they show up in timelines and budgets.
The problem is that those signals surface late, context is fragmented across systems, and decisions slow down while teams chase the “why.” By the time the story is clear, the trial has already absorbed avoidable cost, time, and risk.
Clinical teams don’t need more reporting. They need earlier detection, faster interpretation, and confident action.
That’s what OmniScience delivers.
Sponsors have invested heavily in analytics spanning dashboards, operational metrics, and predictive models. These tools help, but they rarely change the reality of execution:
• Teams review metrics after the fact
• Anomalies are discovered late
• Root cause analysis is manual
• Decisions wait on “one more cut” of the data
• Action happens only after impact is already locked in
Even the best dashboards typically answer one question: what happened? They don’t reliably answer the questions that drive execution, like:
• What changed?
• Why did it change?
• Where is it happening?
• Does it matter enough to act now?
• What interventions are most likely to work?
In reality, teams rarely know the precise set of questions they’ll need to ask to keep a trial on track and they shouldn’t have to.
Consider common scenarios like these:
• Enrollment is slowing. Dashboards show the metric. They don’t explain why it’s slowing at specific sites or what will fix it. Is it screen failure drift? coordinator turnover? referral drop-off? activation delays? competing studies? upstream operational breakdown?
• Adverse events appear imbalanced. Dashboards can flag the difference. They don’t tell you whether it’s real clinical risk, expected variation, cohort mix, or a reporting artifact.
• Protocol deviations are rising. Dashboards track counts. They don’t distinguish isolated noise from early warning signs of downstream endpoint risk or inspection exposure.
• Retention is falling. Dashboards report dropout rates. They don’t identify which subjects are most likely to drop? Or what interventions are most likely to work.
As trials scale in complexity, the problem gets worse: dashboards multiply across functions, vendors, and stakeholders. Teams spend more time reconciling data and rebuilding context than acting on what the trial needs.
That’s considered normal today. We believe it’s unnecessary.
OmniScience is leading the shift from episodic to continuous oversight, powered by agentic AI.
With Vivo, signals aren’t trapped inside disconnected systems and periodic dashboards. Trial data is unified across the clinical ecosystem and monitored continuously, so teams can detect meaningful change earlier and intervene while actionable options still exist.
Vivo is designed to quickly answer the questions that actually drive execution. Humans remain accountable for decisions. OmniScience removes the friction that slows them down.
For clinical operations and development leaders, the benefit is practical and immediate: improved vendor oversight, fewer surprises, faster decisions, and more control over timelines, cost, and risk.
The clinical trial world is moving toward a more continuous, event-based model, one where study success criteria can be defined clearly, monitored continuously, and surfaced as meaningful signals as a trial unfolds.
That shift changes what sponsors should demand from technology.
It’s no longer enough to generate reports after the fact. Sponsors need systems that can:
• Monitor study execution continuously
• Detect drift early
• Interpret what’s driving it
• Guide action before impact is locked in
This is exactly the operating model Vivo was designed for from day one. Not as another dashboard layer, but as a true clinical trial control tower.
This isn’t a vision of the future.
Today, OmniScience Vivo is helping sponsors running active trials reduce preventable delays, avoid unnecessary cost, and manage clinical risk proactively.
OmniScience is building for what comes next. If your teams are still relying on reactive dashboards and manual triage to run trials, and you’d like to explore a better way, contact us to learn more.
